Amivantamab Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies
Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
Amivantamab–Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies
Amivantamab (RYBREVANT) with or without lazertinib (LAZCLUZE) is projected to generate the highest US EGFR-mutated non-small cell lung cancer (NSCLC) therapy revenue in 2036, ahead of AstraZeneca’s osimertinib (TAGRISSO). The shift underscores growing competition across post-TAGRISSO treatment, EGFR exon 20 insertions, and uncommon mutations as TKIs, antibody-drug conjugates (ADCs), bispecific antibodies, CDACs, and combination regimens converge.
EGFR NSCLC Market Forecast and Regional Breakdown
The study evaluates therapy-level revenue, market share, launch timing, peak patient share, uptake curves, treatment switching, pricing, reimbursement, patent exposure, and country-level access. First-line treatment costs show significant variation, ranging from approximately USD 8,747 for platinum-based chemotherapy and USD 27,943 for first- and second-generation TKIs to approximately USD 212,580 for osimertinib.
Adoption of amivantamab plus chemotherapy and amivantamab plus lazertinib is expected to be moderate as these regimens move into earlier treatment lines. Firmonertinib may achieve faster uptake based on clinical positioning, while pamvatamig with or without osimertinib and telisotuzumab adizutecan plus TAGRISSO may require stronger comparative evidence to accelerate adoption.
Research Methodology
The 2022–2036 forecast uses epidemiology-based bottom-up modeling across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Secondary research is validated through primary interviews with more than 15 country-level key opinion leaders and subject-matter experts, including specialists affiliated with the Ohio State University, Norris Comprehensive Cancer Center, and the University of Southern California.
Competitive assessment incorporates SWOT and conjoint analysis, ranking therapies by efficacy, safety, administration, market-entry timing, probability of success, and addressable patient pool. The AI-enabled analysis also covers clinical and regulatory milestones, patents, collaborations, strategic partnerships, treatment algorithms, real-world prescribing, unmet needs, pricing analogues, reimbursement, and market access.
Strategic Value for Market Intelligence Teams
The report supports competitor benchmarking, pipeline prioritization, indication strategy, launch planning, market-access assessment, and scenario forecasting. It identifies revenue opportunities by geography, mutation segment, drug class, therapy, and treatment line while examining how resistance, CNS metastases, affordability, diagnostic testing, and post-targeted-therapy gaps may influence market share through 2036.
Scope of the Report
Report Highlights
Key Questions Answered
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
Reasons to buy
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/f3ub1b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.